JP2016193917A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016193917A5 JP2016193917A5 JP2016105792A JP2016105792A JP2016193917A5 JP 2016193917 A5 JP2016193917 A5 JP 2016193917A5 JP 2016105792 A JP2016105792 A JP 2016105792A JP 2016105792 A JP2016105792 A JP 2016105792A JP 2016193917 A5 JP2016193917 A5 JP 2016193917A5
- Authority
- JP
- Japan
- Prior art keywords
- sulfate
- oso
- oligosaccharide
- pharmaceutical composition
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 22
- 229920001542 oligosaccharide Polymers 0.000 claims 18
- -1 anion oligosaccharide Chemical class 0.000 claims 16
- 150000002482 oligosaccharides Chemical class 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 229920000447 polyanionic polymer Polymers 0.000 claims 7
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims 6
- DBTMGCOVALSLOR-UHFFFAOYSA-N 32-alpha-galactosyl-3-alpha-galactosyl-galactose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(OC2C(C(CO)OC(O)C2O)O)OC(CO)C1O DBTMGCOVALSLOR-UHFFFAOYSA-N 0.000 claims 6
- RXVWSYJTUUKTEA-UHFFFAOYSA-N D-maltotriose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 RXVWSYJTUUKTEA-UHFFFAOYSA-N 0.000 claims 6
- FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 claims 6
- FYGDTMLNYKFZSV-BYLHFPJWSA-N β-1,4-galactotrioside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-BYLHFPJWSA-N 0.000 claims 6
- ZCLAHGAZPPEVDX-UHFFFAOYSA-N D-panose Natural products OC1C(O)C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC1COC1C(O)C(O)C(O)C(CO)O1 ZCLAHGAZPPEVDX-UHFFFAOYSA-N 0.000 claims 4
- 150000001450 anions Chemical class 0.000 claims 4
- ZCLAHGAZPPEVDX-MQHGYYCBSA-N panose Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@@H]1CO[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ZCLAHGAZPPEVDX-MQHGYYCBSA-N 0.000 claims 4
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 claims 3
- 229930091371 Fructose Natural products 0.000 claims 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 2
- 239000005715 Fructose Substances 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 102000006947 Histones Human genes 0.000 claims 2
- 108010033040 Histones Proteins 0.000 claims 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- LUEWUZLMQUOBSB-UHFFFAOYSA-N UNPD55895 Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(OC3C(OC(O)C(O)C3O)CO)C(O)C2O)CO)C(O)C1O LUEWUZLMQUOBSB-UHFFFAOYSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 229930182830 galactose Natural products 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- UYQJCPNSAVWAFU-UHFFFAOYSA-N malto-tetraose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)O1 UYQJCPNSAVWAFU-UHFFFAOYSA-N 0.000 claims 2
- LUEWUZLMQUOBSB-OUBHKODOSA-N maltotetraose Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O[C@@H]3[C@@H](O[C@@H](O)[C@H](O)[C@H]3O)CO)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-OUBHKODOSA-N 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims 1
- 125000001547 cellobiose group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 0 CC1(C(C*)OC(*)C(*)C1*)OC(C(C1*)*=C)OC(C*)C1OC1OC(C*)C(*)CC1* Chemical compound CC1(C(C*)OC(*)C(*)C1*)OC(C(C1*)*=C)OC(C*)C1OC1OC(C*)C(*)CC1* 0.000 description 3
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41882610P | 2010-12-01 | 2010-12-01 | |
| US61/418,826 | 2010-12-01 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013541148A Division JP2014501730A (ja) | 2010-12-01 | 2011-11-29 | ヒストン阻害 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016193917A JP2016193917A (ja) | 2016-11-17 |
| JP2016193917A5 true JP2016193917A5 (enExample) | 2017-02-23 |
| JP6142039B2 JP6142039B2 (ja) | 2017-06-07 |
Family
ID=46171086
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013541148A Pending JP2014501730A (ja) | 2010-12-01 | 2011-11-29 | ヒストン阻害 |
| JP2016105792A Active JP6142039B2 (ja) | 2010-12-01 | 2016-05-27 | ヒストン阻害 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013541148A Pending JP2014501730A (ja) | 2010-12-01 | 2011-11-29 | ヒストン阻害 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9226939B2 (enExample) |
| EP (1) | EP2646037B1 (enExample) |
| JP (2) | JP2014501730A (enExample) |
| KR (1) | KR101956335B1 (enExample) |
| CN (1) | CN103402526B (enExample) |
| AU (1) | AU2011335881B2 (enExample) |
| BR (1) | BR112013013544B1 (enExample) |
| CA (1) | CA2819642C (enExample) |
| DK (1) | DK2646037T3 (enExample) |
| ES (1) | ES2710857T3 (enExample) |
| HU (1) | HUE043546T2 (enExample) |
| IL (1) | IL226667A (enExample) |
| NZ (1) | NZ611316A (enExample) |
| SG (1) | SG190438A1 (enExample) |
| WO (1) | WO2012071611A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3105593B2 (ja) | 1991-10-18 | 2000-11-06 | 東海パルプ株式会社 | パルパー制御装置 |
| CN110446511B (zh) | 2017-03-10 | 2024-04-02 | 北卡罗来纳大学查珀尔希尔分校 | 短效的基于肝素的抗凝血剂化合物和方法 |
| US11993627B2 (en) | 2017-07-03 | 2024-05-28 | The University Of North Carolina At Chapel Hill | Enzymatic synthesis of homogeneous chondroitin sulfate oligosaccharides |
| EP3691653B1 (en) | 2017-11-03 | 2025-03-12 | The University Of North Carolina At Chapel Hill | Sulfated oligosaccharides having anti-inflammatory activity |
| CN117427084A (zh) | 2017-12-15 | 2024-01-23 | 澳大利亚国立大学 | 用于治疗和预防细胞外组蛋白介导的病理的化合物 |
| EP3810152A4 (en) * | 2018-06-20 | 2022-04-27 | The University of North Carolina at Chapel Hill | CELL PROTECTION METHODS AND COMPOSITIONS |
| WO2020033824A1 (en) * | 2018-08-09 | 2020-02-13 | University Of Vermont And State Agricultural College | Inhibitors of acute severe inflammatory conditions |
| CN113473992A (zh) * | 2019-02-25 | 2021-10-01 | 澳大利亚国立大学 | 用于治疗和预防中性粒细胞胞外陷阱相关并发症的化合物 |
| WO2022116981A1 (zh) * | 2020-12-01 | 2022-06-09 | 远大医药（中国）有限公司 | 一种聚阴离子纤维二糖苷类化合物的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4847338A (en) | 1985-03-28 | 1989-07-11 | University Of Iowa Research Foundation | Low molecular weight heparin fragments as inhibitors of complement activation |
| DK505488D0 (da) * | 1987-12-21 | 1988-09-09 | Bar Shalom Daniel | Middel og anvendelse af samme |
| US5583121A (en) | 1994-01-12 | 1996-12-10 | Michigan State University | Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes |
| US5792241A (en) | 1994-09-21 | 1998-08-11 | Allrad No. 28 Pty Ltd. | Precipitator |
| AUPN261895A0 (en) * | 1995-04-28 | 1995-05-18 | Australian National University, The | Preparation and use of sulfated oligosaccharides |
| WO1999004826A1 (en) | 1997-07-24 | 1999-02-04 | The Australian National University | Method for detection of fibrin clots |
| ITMI20021294A1 (it) | 2002-06-12 | 2003-12-12 | Inalco Spa | Polisaccaridi batterici o-solfatati e loro uso |
| US20050282775A1 (en) * | 2004-06-16 | 2005-12-22 | Paringenix, Inc. | Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome |
| US7468358B2 (en) * | 2004-06-16 | 2008-12-23 | Paringenix, Inc. | Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (HIT) syndrome |
| US20060229276A1 (en) | 2004-07-28 | 2006-10-12 | Magnus Hook | Use of glycosoaminoglycans for the prevention and treatment of sepsis |
| PT1877105E (pt) | 2005-04-29 | 2013-11-11 | Univ Australian | Método para formar uma composição radioativa injetável de partículas radioativas encapsuladas em carbono |
| EP1747785A1 (en) | 2005-07-28 | 2007-01-31 | Istituto Clinico Humanitas | Cyclodextrins for blood detoxification |
| WO2007062403A2 (en) | 2005-11-28 | 2007-05-31 | Vernon D Rowe | Compositions useful for reducing nephrotoxicity and methods of use thereof |
| WO2007095688A1 (en) * | 2006-02-23 | 2007-08-30 | The Australian National University | Methods for increasing the number of circulating cells |
| GB2450087A (en) * | 2007-06-11 | 2008-12-17 | Diosamine Dev Corp | Use of sulphated saccharides in the treatment of inflammatory and/or auto-immune diseases |
| US8716218B2 (en) * | 2007-11-06 | 2014-05-06 | Oklahoma Medical Research Foundation | Extracellular histones as biomarkers for prognosis and molecular targets for therapy |
| EP2282782B1 (en) | 2008-04-24 | 2018-01-24 | The Australian National University | Methods for radiolabelling macromolecules |
| JP2011256111A (ja) * | 2008-10-03 | 2011-12-22 | Hayashibara Biochem Lab Inc | 敗血症の予防及び治療剤 |
-
2011
- 2011-11-29 NZ NZ611316A patent/NZ611316A/en unknown
- 2011-11-29 SG SG2013041579A patent/SG190438A1/en unknown
- 2011-11-29 JP JP2013541148A patent/JP2014501730A/ja active Pending
- 2011-11-29 ES ES11845528T patent/ES2710857T3/es active Active
- 2011-11-29 HU HUE11845528A patent/HUE043546T2/hu unknown
- 2011-11-29 BR BR112013013544-1A patent/BR112013013544B1/pt active IP Right Grant
- 2011-11-29 KR KR1020137016013A patent/KR101956335B1/ko active Active
- 2011-11-29 EP EP11845528.6A patent/EP2646037B1/en active Active
- 2011-11-29 WO PCT/AU2011/001550 patent/WO2012071611A1/en not_active Ceased
- 2011-11-29 AU AU2011335881A patent/AU2011335881B2/en active Active
- 2011-11-29 US US13/990,031 patent/US9226939B2/en active Active
- 2011-11-29 CN CN201180066031.1A patent/CN103402526B/zh active Active
- 2011-11-29 DK DK11845528.6T patent/DK2646037T3/en active
- 2011-11-29 CA CA2819642A patent/CA2819642C/en active Active
-
2013
- 2013-05-30 IL IL226667A patent/IL226667A/en active IP Right Grant
-
2016
- 2016-05-27 JP JP2016105792A patent/JP6142039B2/ja active Active